Did Moderna Just Jump Ahead of Rivals in a Potential Billion-Dollar Market?

The initial early pandemic vaccine race came to a close long ago, but there's a new race going on -- and one that could be worth billions of dollars in recurring revenue. I'm talking about the race to develop a single product that could protect the population from flu and coronavirus. Vaccine leaders Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are making gains in this competition, as is smaller rival Novavax (NASDAQ: NVAX).

All three companies are studying combined vaccines in clinical trials, and so far, the results have been promising. This week, Moderna reported the latest from its phase 1/2 study and said it was ready to start a phase 3 trial. It even said it aims to launch its combined product in 2025. Did Moderna just jump ahead of its vaccine rivals?

First, a little background on today's vaccine situation. Pfizer has been the leader, so far, with 65% share of the U.S. market in the first six months of this year. That's worked out fine for Moderna, though, as the company still has generated billions of dollars in revenue from its vaccine, peaking at more than $18 billion last year. 

Continue reading

Source Fool.com